DNTH Stock: Earnings, Dividends & Analyst Estimates

Company Overview:

Market Cap: $5.26B

Trailing PE: N/A

FWD PE: —

Payout Ratio (TTM): —

52-Week Range: $34.29 - $117.88

5.2 Year DNTH Performance Metrics:

Total Return (with DRIP): -9.9% (-1.99% CAGR)

Total Return (no DRIP): -9.9% (-1.99% CAGR)

Share Price: -9.9% (-1.99% CAGR)

Yield on Cost (with DRIP): —

Total Invested: $10,000

Total Value (with DRIP): $9,008

Total Return $ (with DRIP): -$992

DNTH Total Return

1M 3M 6M YTD 1Y 3Y 5Y 10Y

DNTH Price Chart

1M 3M 6M YTD 1Y 3Y 5Y 10Y All

Build Custom Charts

DNTH - Chart 1

DNTH - Chart 2

DNTH - Chart 3

DNTH Financials: Earnings, Revenue, Cash Flow, Ebitda, Cash/Debt, Shares Float, etc:

Revenue

DNTH Revenue CAGR:1Y: 205.56%2Y: -25.36%5Y: 0.00%10Y: 0.00%

Earnings Per Share (EPS)

DNTH EPS CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

Net Income

DNTH Net Income CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

EBITDA

DNTH EBITDA CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

Free Cash Flow

DNTH Free Cash Flow CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

Free Cash Flow / Share

DNTH Free Cash Flow / Share CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

Operating Income

DNTH Operating Income CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

Gross Profit

DNTH Gross Profit CAGR:1Y: 205.56%2Y: -25.36%5Y: 0.00%10Y: 0.00%

Shares Outstanding

DNTH Shares Outstanding CAGR:1Y: 51.72%2Y: 29.42%5Y: 73.37%10Y: 0.00%

Share Buybacks

DNTH Share Buybacks CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

Stock-Based Comp

DNTH Stock-Based Comp CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

Expenses

DNTH Expenses CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

Revenue vs Net Income

EPS vs FCF / Share

EPS vs PE Ratio

FCF vs FCF / Share

FCF vs Stock Based Comp

Cash & Debt

Revenue by Segment

DNTH Revenue CAGR:1Y: 205.56%2Y: -25.36%5Y: 0.00%10Y: 0.00%

Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:

REVENUE: Actual + Estimates

DNTH Actual Revenue CAGR:1Y: 205.56%2Y: -25.36%5Y: 0.00%10Y: 0.00%

EPS: Actual + Estimates

DNTH Actual EPS CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

NET INCOME: Actual + Estimates

DNTH Actual Net Income CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

EBITDA: Actual + Estimates

DNTH Actual EBITDA CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

Ratios, Profit Margins & Return on Capital:

Net Profit Margin

DNTH Net Profit Margin CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

Gross Profit Margin

DNTH Gross Profit Margin CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

Price to Earnings

DNTH Price to Earnings CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

Price To Sales Ratio

DNTH Price To Sales Ratio CAGR:1Y: 11.11%2Y: 210.94%5Y: 0.00%10Y: 0.00%

Return on Capital Employed

DNTH Return on Capital Employed CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

Return on Invested Capital

DNTH Return on Invested Capital CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

Projected Future Returns & Dividends for DNTH

Based on past 5.2-year performance, here are DNTH growth metrics:

Share price CAGR of -1.99%
Dividend CAGR of +0%

Using DNTH CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:

	DNTH (DRIP)	DNTH - No DRIP
Current Price	$91.81	$91.81
Start Shares	108.92	108.92
Start Value	$10,000	$10,000

After 10 years:
Final Share Count	108.92	108.92
Dividends Payment	$0.00	$0.00
Annual Dividends	$0	$0
Yield on cost	0.00%	0.00%
Share Price	$75.10	$91.81
Total Dividends	$0	$0
Final Value	$8,180	$10,000

Estimated Future Value + Dividends - DNTH

NOTE: Above numbers are our estimate based on DNTH's Dividend and Price CAGR over past 5.2 years. These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.

We cannot guarantee that your actual returns will meet these estimates.

Company Info

Dianthus Therapeutics, Inc. (DNTH) had its IPO on , and is traded on NASDAQ stock exchange.

DNTH website: https://dianthustx.com

Loading signals…

DCF Model — DNTH

Value from:

EPS (TTM)icompany profit per share over the last 12 months

EPS Growth %ihow fast profit per share grows each of the next 5 years — prefilled with what analysts expect

EPS growth after year 5 (forever)ithe slower pace once the fast 5 years are over — only drives years 6-10 of the price path below

Exit multiple (PE in 5 yrs)iwhat buyers pay per $1 of profit in 2031 — prefilled with today’s forward PE

Desired return %/yrithe yearly return you want from buying today — the S&P has done ~14%/yr, ask for more from a single stock

FCF growth %/yr (next 5 yrs)ihow fast free cash flow grows while the company is still expanding fast

Years of fast FCF growthihow many years the fast growth lasts before the business settles down

FCF growth after year 5 (forever)ithe slow, steady pace once the company is mature — usually 2-3%, near inflation. Must stay below your target return

Risk-free rate %iwhat a 10-yr US treasury pays with zero risk — the floor any risky stock must beat

Your target return %/yrithe yearly return you want for taking this risk — rule of thumb: risk-free rate + extra for risk

FCF base ($M, TTM)ilast 12 months of free cash flow, added up from reported quarters

Include dividends in returnidividends hand you part of the return in cash, so the share price needs to climb less

Pay up to today

—

vs current price $91.81

—

Cash flow & implied price by year

FCF is negative or missing for this company (common for banks) — the model discounts EPS instead.

EPS is negative or missing for this company — Simple mode uses free cash flow per share instead.

Free cash flow today

—

grows for the next years

Then mature

—

every future dollar counted back to today

Pile of today-dollars

—

÷ shares

Implied price path

Year	FCF	Implied price

Sensitivity — fair value: growth ↓ × target return →

Dianthus Therapeutics, Inc. DNTH | NASDAQ